Title of Invention

A PROCESS FOR THE PREPARATION OF 7α-METHYLSTEROIDS

Abstract

The present invention relates to a process for the preparation of 7a-methyl steroids of the Formula I: wherein R<SUb>1</SUB> is hydrogen, methyl or C=CH; R<SUb>2</SUB> is (CH<SUb>2</SUB>)nOH, wherein n is 0, 1 or 2; by a copper catalyzed 1,6-conjugate addition of a Grignard reagent CH<SUb>3</SUB>MgX, X being a halogen, to the 4,6-unsaturated 3-ketosteroid of formula II: wherein R<SUb>1</SUB> and R<SUb>2</SUB> are as previously defined, comprising the steps of protecting the hydroxy group of the steroid of Formula II with a trialkylsilyl group, followed by treating the hydroxy protected steroid with the Grignard reagent.

Full Text

7a-Methylsteroids represent an important class of pharmacologically active compounds. One example of a steroid with a methylgroup at the 7-position is (7a,17a)-17-hydrox>'-7-methyl-19-norpregn-5(10)-en-20-}'n-3-one (Tibolone) which is the active component of Livial®, used as hormone replacement therapy in the treatment of menopausal complaints. Tibolone is a compound exerting tissue-specific hormonal activity. In laboratory and cliirical studies, Tibolone exerts estrogenic effects on the thermoregulatory system,, vaginal tissue and bone, but does not display estrogenic activity on breast or the endometrium. Tibolone's promising effects on bone are also currently under investigation for the prevention of osteoporosis in women who are likely to develop this condition. {1) Pavlov, P.W., et al. Gynecol. Endocrinol. 1999;13: 230-237, 2) Tibolone (Livial). A new steroid for the menopause. Drug Tlrer. Bull. 1991;29:77-S, 3) Moore R.A. Systematic and economical review for Livial. In: Rymer J (Ed.), Livial: A review of clinical studies. Br.IGynaecol. 1999;106 (3 Suppl. 19) 1) Another pharmacological important class of 7a-methylsteroids are 7a-methyl-19-norrestosterone (MENT™) and the related esters at the 17-position (W099/67271), which are synthetic androgens being developed for hormone replacement therapy and male fertility control. Studies have shown MENTTM to be more potent than the male hormone testosterone in maintaining muscle mass, potency, and libido and in its ability to suppress sperm production. Also, MENTm does not enlarge the prostate as much as testosterone does, which may result in safer medical use. {1) Ogawa, S., et al. 1996; 30:74-84. Hormones and Behavior, 2) Robbing, _A., et al. Society for Neuroscience.Abstracts 1994;20 (part 1):376, 3) Sundaram, K., et al. Annals of Medicine 1993;25:199-205, 4) Morali, G. et al Biology of Reproduction 1993;49:577-581). A third example of a potential interesting steroid with a methylgroup at the 7-position is 3-hydroxy-7a-methyl-21-[2"-methoxy-4'-(diethylaminomethyI)-phenoxy]-19-norpregna-l,3,5(10)triene citrate (SR 16234), which is a Selective Estrogen Receptor Modulator (SERM) which has been found to have potent antitumor activity with tissue selective properties, and complete antagonist-antiestrogenic activity in human breast tumor cells. (1) WO 01/58919 A2, 2) WO 99/33859 A2, 3) US 6,281,205 B1,4)US 20020032180 Al). From a synthetic point of view, the stereoselective introduction of the substituents at C-7 constitutes the key transformation in the assembly of representatives from this important class of steroids. According to hterature, the introduction of an alkyl group in the 7-position of a steroid backbone is generally accomplished by a) cuprous chloride or cupric acetate catalyzed 1,6-conjugate addition of alkybnagnesiumhalogens to 4,6-unsaturated 3-keto steroids, or b) by conjugate addition of copper-Iithiuraalkyl-reagents to 4,6-unsaturated 3-ketosteroids. However, in general these methods yield mixtures of 7a- and 7P-alkylsteroids (1) Modi, S.P. et al, J. Org. Chem. 1989;54: 2317-2321, 2) GmnweU, J. F. Steroids, 1976;27: 6, 759. 3) CampbeU, J.A. et al, J.Am.Chem.Soc. 1959;S1: 4069, 4) Grunweli, J.F., et al. Steroids 1976;27: 750, 5) US patent 3,798,213, 6) van Vliet N.P., et al. Recl.Trav.Chim.Pays-Bas 1986;105:111) in ,P-ratios ranging from 1.5:1 to 9:1. Isolation of the pharmacological interesting 7a-isomers from the accompanying undesirable 7B-isomers, which are less effective enzyme inhibitors (O'Reilly, J.M. et al. J. Med. Chem. I995;38: 2842) only can be achieved by chromatographic separation, or by-laborious work-up procedures by repetitive recrystallization. Both operations decrease the yield of the desired 7a- isomer significantly. In WO 01/58919, a 4,6-unsaturated 3-ketosteroid is alkylated at the 7-position with methyllithium in the presence of lithium bromide. In this case it is reported that the stereoselectivity of this 7-aIkylation increases after protecting the extant hydroxylgroup with a THP-ether, allegedly by complex formation with the hthium in favor of attack from the a-face of the steroid. Despite the increase in selectivity, unfortunately in this last method the high reactivity of the acetate protecting group with the methyUithium is reflected in only a moderate yield of 67% of the 7a-methylsteroid. Alternative methods for the introduction of 7-alkylgroups have been developed, but are not generally applicable. Only a limited selection of alkylgroups can be introduced, the method is limited to the synthesis of steroids with an aromatic A-ring, or additional reaction steps are required, making these methods generally inefficient. For example: 7a-substituted estradiols have been prepared by conversion of 6-ketoestradiols into 6-(phenylsulfonyl)-6- " dehydroestradiol, which undergoes conjugate addition of organolithium reagents to the C-7-position, followed by additional steps to remove the sulfone group. (Kunzer, H. et al. Tetralredron Lett. 1994;35: 11, 1691) In a more recent approach 7a-substituted estradiols have been prepared by alkylation of 6-ketoestradiols, followed by deoxygenation and deprotection with boron trifluoride etherate and triethylsilane. (Tedesco, R. et al. Tetrahedron Lett. 1997;38: 46, 7997). In WO 01/58919, a 6-ketoestradiol is alkylated at the 7-position by reaction with methyl iodide in the presence of lithium diisopropylamine, followed by cataytic removal of the 6-ketone using hydrogen and platinum and palladium; reported is that the stereoselectivity of this 7-alkylation increases after protection of the extant hydroxylgroup with a THP-ether, allegedly by steric hindrance from the B-face of the steroid. la DE 4,018,828 A it is described that 7a-methylestradiols were prepared by a sequence of reactions irom 8,9-unsaturated estradiols with formaldehyde in the presence of Lewis acids, followed by catalytic hydrogenation, tosylatioru and reduction. In EP 0,262,201 Bl the preparation of 7a-propylsteroids is described from 4,6-imsaturated 3-ketosteroids by a Sakurai reaction of aUyltrialkylsilanes or aUyltrialkyltin compounds in the presence of Lewis acids, followed by a selective hydrogenation with tris(triphenylphosphine)rhodium(I)-chloride (Wilkinson's catalysts), (see also Nickisch, K; Laurent, H. Tetrahedron Lett. 1988;29: 13, 1533). Therefore, a major challenge rn the synthesis of 7-alk>dsteroids is control of the diastereoselectivity of the copper mediated 1,6-coniugate addition, which is the most straightforward method of introduction for 7-alkylgroups. wherein Rl and R2 are as previously defined, comprising protecting the hydroxy group of the steroid of formula II with a trialkylsilyl group, followed by treating the hydroxy' protected steroid with the Grignard reagent. The process of this invention results in a major increase in solubliity of the steroid substrate, opens up the possibility to increase the concentration of steroid substrates in said process (a range of concentrations is possible, but preferably the concentration of the steroid is 0.1 to 0.3 molar), and surprisingly shows a markedly improved stereoselectivit}' in favor of the desired 7a-isomer. The levels of the unwanted 7β-isomer are decreased to levels below 2.5%, which is a more than sixfold improvement in selectivity (irom approximately 6:1 to 39: 1). Although the trialkylsilyl protection of a hydroxy group in a process wherein a 7a-ethyl group was introduced has been described previously (WO 01/05806), the reported selectivity was only 85:15 (a:P). Preferably, RI is hydrogen, methyl or C=CH and R2 is OH; or Rl is hydrogen and R2 is (CH2)20H. More preferably, when R2 is OH, Rl is hydrogen or C=CH. The preferred Grignard reagent to be used in the process of the invention is CHaMgCl. ' The Grignard reaction of the process of the invention can be performed in several solvents or mixtures of solvents, which are well known to the person skilled in the art, s\ich as tetrahydrofuran, dimethoxyethane, diethyl ether, mono- and diglyme, toluene and the like. Preferred are tetrahydrofuran or diethyl ether or a mixture of these solvents. Tetrahydroforan is the most preferred solvent. The Grignard reagent is used equimolar or in excess to the steroid. Preferably, the molar ratio of the steroid to the Grignard reagent is 1:1 to 1:7. The step wherein the trialkylsilyl protective group is introduced according to the process of the invention can be integrated in the 1,6-conjugate addition reaction, retaining the improved stereoselectivity in favor of the desired 7a-isomer and without loss of yield. The term "alk}T' used herein means a (l-4C)aIkyl group, being a branched or unbranched alkyl group having 1 to 4 carbon atoms, in particular methyl or ethyl. The preferred protective groups are trimethylsUyl or triethylsilyl; most preferred is trimethylsilyl. In the process of this invention a copper catalyst is used to catalyze the Grignard reaction, such as copper(II) acetate, copper(II) choride, copper(n) bromide, copper(II) iodide and the like. The preferred catalysts are selected from copper(n) acetate or copper(II) chloride. The most preferred catalyst is copper(II)acetate. The reaction temperature of the Grignard reaction of the process of the invention is not very critical, but should be kept low, preferably between -78 °C and 0 °C. The preferred temperature range is from -35 °C to -25 °C. TMs new process for the first time makes a straightforward approach available for increasing the stereoselectivity of copper catalyzed 1,6-conjugate addition of methyknagnesiumhalogens to hydroxylated 4,6-unsaturated 3-ketosteroids. Consequently,, laborious v/ork-up procedures by troublesome chromatographic separations or by repetitive recrystallization are unnecessary. In a suitable process of the invention a hydroxy 4,6-unsaturated 3-ketosteroid is treated with a trialkylsilyl reagent to protect the hydroxy functionality, after which a solution of the silyl protected steroid is added to a mixture of the copper catalyst and the Grignard reagent in an appropriate solvent, which after stirring for some time is followed by removal of the protective group. Removal of the trialkysilyl protective group takes place under the typical conditions needed for the conjugation to the 4-unsaturated 3-ketosteroids, resulting in an effective one-step procedure. Suitably, the process is finalized by acid treatment for both removal of the trialkylsilyl group and equilibration of the 3,5-unsaturated magnesium-enolate to the desired 7a-methylsteroids of the formula I. The process of the invention is particularly useful for the preparation of 7a-methylsteroid (7a,17a)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one, suitable for preparation of (7a,17a)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Tibolone), for the preparation of 7a-methyl-19-nortestosterone (MENT), and for the preparation of (7a)-21-hydroxy-7-methyl-19-norpregn-4-en-3-one, suitable for the preparation of 3-hydroxy-7a-methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-l,3,5(10)triene citrate (SR 16234). For comparison, without introduction of a trialkylsilyl protective group, MENT was prepared by a copper catalyzed 1,6-conjugate addition from 17|3-17-hydroxy-estra-4,6-diene-3-one in approximately 55% yield, with a 7a,p-ratio of 85:15 (according to procedures described in US 5,342,834; FR 4.521 M). Isolation of the 7a-isomer could only be achieved by repeated crystallizations iiom respectively heptane, and aqueous acetone, decreasing the overall yield to a moderate 44%. In a suitable process according to the invention, introduction of a trimethylsilyl protective group before the 1,6-conjugate addition reaction increases the overall yield of MENT to 79%, which is an improvement of the overall yield by 80%. \ fiirther object of the present invention is the compound 21-hydroxy-19-norpregn-4,6-dien-3-)ne, which is a suitable intermedaite for use in the process of the present invention for the )reparation of (7a)-21-hydroxy-7-methyl-19-norpregn-4-en-3-one, which in turn is suitable for he preparation of 3-hydroxy-7a-methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-l,3,5(10)triene citrate (SR 16234). The invention is further illustrated by the following examples, which does not mean any limitation. EXAMPLES EXAMPLE 1. 7a—methyl-19-nortestosterone (IvIENT). Chlorotrimethylsilane (34.4 ml, 370 mmol) was added drop\vise under nitrogen atmosphere at 20°C to a solution of (17p)-17-hydroxy-estra-4,6-diene-3-one (25 g, 92 mmol) (Wettstein, A. Helv.Ghim.Acta, 1940;23: 388) and triethylamine (50 ml, 350 mmol) in anliydrous tetrahydrofuran (250 ml). The resulting mixture was stirred at reflux for 2 h. The reaction mixture was cooled to room temperature, water (125 ml) was added and the mixture was extracted with toluene (250 ml). The combined organic layer was washed with an 10% aqueous sodium chloride solution (125 ml) and evaporated under reduced pressure to yield the 17-trimethylsilyloxy-intermediate as a residual solid, which without isolation was dissolved in anhydrous tetrahydrofuran (250 ml). This solution was added at -30°C in 2 h to a mixture of copper(n) acetate (2.58 g, 12.5 mmol) and a 3M solution of methymagnesium chloride (61.6 g, 185 mmol) in tetrahydrofuran (120 ml), and the orange-red solution was stirred at -30°C for 1 h. Next the reaction mixture was poured into a solution of sulfuric acid (36.5 ml, 681 mmol) and water (500 ml) and stirred at 40°C for 2.5 h. Sodium acetate was added to a pH of 3.5, and the mixture was extracted with ethyl acetate (260 ml) and washed with aqueous ammonium chloride (83 ml, 10%). After removal of solvents by evaporation under reduced pressure aqueous acetone (150 ml, 50%) was added, and at -10°C 7a-methyl-19-nortestosterone (MENT) was crystallized (19.6 g, 79%) (in accordance to US 5,342,834; FR 4.521 M) in a 7a,P-ratio of 99:1. 'H-NMR (400 AlHz, CDCI3): 5 5.68 (bt. IH, C(4)H), 3.54 (t, IH, C(17)H), 2.37-0.88 (m, 19H), 0.66 (s, 3H, C(l8)H3), 0.61 (d, 3H, C(7)CH3). EXAMPLE 2. (7a, 17a)-17-Hydroxy-7-methyl-19-norpregn-4-en-20-3'n-3 -one. Chlorotrimethylsilane (6.28 ml, 67.5 mmol) was added dropwise under nitrogen atmosphere at 20°C to a solution of (17a)-17-hydroxy-19-norpregna-4,6-dien-20-yn-3-one (5.0 g, 17 mmol) (GB 935116) and pyridine (11.4 ml, 142 mmol) in anhydrous tetrahydrofuran (50 ml). The resulting mix-ture was stirred at reflux for 2.5 h. The reaction mixture was cooled to room temperature, water (25 ml) was added and the mixture was extracted with toluene (50 ml). The combined organic layer was washed with aqueous .methanol (25 ml, 70%)) and evaporated under reduced pressure to yield the 17-trimethylsilyloxy-intermediate as a residual soHd, which without isolation was dissolved in anhydrous tetrahydrofuran (110 ml). This solution was added at-30°C in 2 h to a mixture of copper(II) acetate (0.58 g, 2.9 mmol) and a 3M solution of methylmagnesium chloride (40 g, 118 mmol) in tetrahydrofuran (50 ml), and was stirred at -30°C for 1 h. Next the reaction mixture was poured into a solution of sulfuric acid (6.8 ml, 126 mmol) and aqueous tetrahydrofuran (160 ml, 15%) and stirred at 20°C for 8 h. Sodium acetate was added to a pH of 3.5, and after removal of solvents by evaporation under reduced pressure (7a,17a)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one was crystallized (5.2 g, 99%o) (in accordance to literature: Van Vliet, N.P., et al Recl.Trav.Chim.Pays-Bas, 1986;105: 111), in a 7a,β-ratio of 95:5. 'H-NMR (400 MHz, CDCI3): 5 5.86 (bt, IH, C(4)H), 2.59 (s, IH, C(21)H), 2.52-0.86 (m, 19H), 0.94 (s, 3H, C(18)H3), 0.79 (d, 3H, C(7)CH3). EXAMPLE 3. 21 -hydroxy-19-norpregn-4,6-dien-3-one. 4-Toluenesulfonic acid (100 mg, 0.56 mmol) was added under a nitrogen atmosphere at -5 °C to a suspension of 21-hydroxy-19-norpregna-4-en-3-one (30.0 g, 99.2 mmol) (WO 01/58919) and triethyl orthoformiate (22.1 mL, 133 mmol) in ethanol (60 mL). After being stirred for 2 h at 0 °C the reaction mixture was quenched with triethylamine (0.22 niL, 1.6 mmol) and heated at reflux for 15 min. The reaction mixture was diluted with ethanol (50 mL), ethyl acetate (1.0 L), water (500 mL) and dichloromethane (500 mL). The organic layer was separated, the aqueous layer was extracted (dichloromethane, 2 x 250 mL) and the combined organic layers were concentrated in vacuo. A solution of the residue (50 g) in THF (140 mL) was added to a suspension of chloranil (26 g, 106 mmol) in methanol (140 mL), water (19 mL), acetic acid (5.1 mL) and pyridine (1.9 mL) at 20 °C. After being stirred at this temperature for 2 h, the reaction was quenched with a solution of sodium hydroxide (42 g, 1.05 mol) and sodium hydrosulfite (4.9 g, 28mmol) in water (490 mL). The aqueous layer was extracted (dichloromethane, 3 x 500 mL), the combined organic layers were washed until pH neutral (water, 4 x 100 mL) and concentrated in vacuo to yield 21-hydroxy-19-norpregn-4,6-dien-3-one (25.0 g, 84%). The product was purified by column chromatography and crystallization from ethyl acetate (10.9 g, 37%). 'H-NMR (400 MHz, CDCI3): 5 6.25-6.17 (ABX dq, 2H, C(6)H and C(7)H), 5.76 (bd, IH, C(4)H), 3.73-3.58 (m, 2H, C(21)H20IT), 2.50-1.08 (m, 19H), 0.69 (s, 3H, C(18)H3) (7a)-21-hydroxy-7-methyl-19-norpregn-4-en-3-one. Chlorotrimethylsilane (2.0 mL, 33.3 mmol) was added dropwise under a nitrogen atmosphere at 20°C to a suspension of 21-hydroxy-19-norpregna-4,6-dien-3-one (5.0 g, 17 mmol) and triethylamine (12 mL, 80 mmol) in anhydrous tetrahydrofuran (100 mL). The resulting mixture was stirred at reflux for 1 h. The reaction mixture was cooled to room temperature, water (50 mL) was added, the organic layer was separated and the water layer was extracted with toluene (25 mL). The combined organic layers were concentrated in vacuo, yielding crude intermediate silylether (11 g). A solution of the silylether in tetrahydrofuran (121 mL) was added in 45 min to a solution of copper acetate (285 mg, 2.86 mmol) and methyl magnesium chloride (3.0 M solution in THF, 38.8 mL, 116 mmol) in THF (45 mL) at -20°C. After being stirred for 1 h at this temperature the reaction was quenched with a solution of sulhrric acid (6.7 g, 68 mmol) in water (125 mL) and THF (25 mL). After being stirred for 17 h at 20°C, the reaction mixture was distilled THF-fiee and the product was extracted with dichloromethane (3 x 50 mL). After concentration in vacuo, (7a)-21-hydroxw-7-methyl-19-norpregn-4-en-3-one was obtained as an amorphous solid (5.2 g, 99%) (in accordance to Uterature WO 01/58919) in a 7a/B ratio of 95:5. 'H-NMR (400 MHz, CDCI3): 5 5.85 (bt, IH, C(4)H), 3.75-3.57 (m, 2H, C(21)H.0H), 2.50-0.97 (m, 22H), 0.77 (d, 3H, C(7)CH3), 0.67 (s, 3LI, C(18)H3). WE CLAIM; 1. A process for the preparation of 7a-methyl steroids of the Formula I: comprising the steps of protecting the hydroxy group of the steroid of Formula II with a trialkylsilyl group, followed by treating the hydroxy protected steroid with the Grignard reagent. 2. The process as claimed in claim 1, wherein Rl is hydrogen, methyl, or C=CH and R2 is OH. 3. The process as claimed in claim 1, wherein Rl is hydrogen and R2 is (CH2)20H. 4. The process as claimed in claims 1 or 3, wherein the Grignard reagent is CH3MgCl. 5. The process as claimed in claims 1 to 3, wherein the trialkylsilyl group is a trimethylsilyl group. 6. The process as claimed in claims 1 to 4, wherein the solvent of the Grignard reaction is tetrahydrofuran, diethyl ether or a mixture thereof. 7. The process as claimed in any one of claims 1 to 5, wherein the concentration of the steroid is 0.1 to 0.3 molar. 8. The process as claimed in any one of claims 1 to 6, wherein the molar ratio of the steroid to the Grignard reagent is 1:1 to 1:7. 9. The process as claimed in any one of claims 1 to 7, wherein the catalyst is copper(II) acetate or copper(II) chloride. 10. The process as claimed in any one of claims 1 to 8, wherein the reaction temperature of the Grignard reaction is -78 °C to 0 °C. 11. The compound 21-hydroxy-19-norpregn-4, 6-dien-3-one.

Documents:

1557-chenp-2004 abstract.jpg

1557-chenp-2004 abstract.pdf

1557-chenp-2004 assignment.pdf

1557-chenp-2004 claims.pdf

1557-chenp-2004 correspondence-others.pdf

1557-chenp-2004 correspondence-po.pdf

1557-chenp-2004 description(complete).pdf

1557-chenp-2004 form-1.pdf

1557-chenp-2004 form-18.pdf

1557-chenp-2004 form-26.pdf

1557-chenp-2004 form-3.pdf

1557-chenp-2004 form-5.pdf

1557-chenp-2004 form-6.pdf

1557-chenp-2004 others.pdf

1557-chenp-2004 pct search report.pdf

1557-chenp-2004 pct.pdf

1557-chenp-2004 petition.pdf